Phase 2B Study to Evaluate the Efficacy of PB2452 in Reversal of Ticagrelor in Subjects Aged 50-80 Years Old
Status:
Completed
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
This phase 2B study is a multi-center, randomized, double-blind, placebo-controlled study.
The study is designed to evaluate the efficacy of PB2452 in reversing the anti-platelet
effects of ticagrelor as part of a dual antiplatelet regimen and to evaluate the safety and
tolerability of PB2452 in subjects aged 50-80 years old.
Approximately 200 subjects between 50-80 years old will be enrolled in the US or other
countries at the discretion of the Sponsor across 5-15 sites. The subjects will be randomized
at a ratio of 3:1 receiving either the PB2452 investigational study drug or placebo. Hence, a
total of approximately 150 subjects will be receiving PB2452 and approximately 50 subjects
will be receiving placebo.